Behind the Scenes of the Drug Approval Process: Containing Ebola

The spread of Ebola is unsettling to many Americans, yet to date the U.S. FDA and the EMA (the FDA’s European counterpart) have not approved any medicines or vaccines to treat a potential global outbreak. In October 2014, both agencies released guidelines for companies to get accelerated approval for potential Ebola treatments; such emergency responses are unprecedented. Why did the FDA and EMA make these rules in the case of Ebola and how will they change the course of drug approval? Harvard University chemist Li Zha explains.

Who Defines What’s “Healthy”? Diagnoses, Treatments, and Medicine’s Mission

As a medical student, I'm perpetually absorbing knowledge taught to me...What all of these teachings share is a certainty that there are problems, and that medical students can learn – through lectures and textbooks and research – how to fix them. I'm still not clear why we're making the attribution of one thing as a problem, and another as the solution.

Examining Ebola Fears & Viral Mutations

Ebola hysteria dominated popular news in 2014. However, since the outbreak began to draw attention in March earlier this year, only two people have been infected in the United States. Did this really warrant non-stop media coverage? Much of this attention may have been attributed in part to the worry that Ebola may “mutate to become airborne,” but is this even something we need to worry about?

An “Imminent Cure” for Diabetes? The Real Story Behind the Headlines

You may have read the recent media stories that a cure for Type I Diabetes is “imminent” and wondered what the buzz was about—is a cure indeed imminent and, if so, what does this mean for modern medicine? Hippo Reads’s Science Correspondent Wudan Yan spoke with Felicia Pagliuca, a postdoc in Melton’s lab, about the work that went into this landmark Harvard study, the importance of collaboration, and where diabetes research will go from here.